---
figid: PMC6218675__fphys-09-01533-g0002
figtitle: Summary of the potential treatments tested so far in EDMD
organisms:
- Saccharomyces cerevisiae
- Schizosaccharomyces pombe
- Homo sapiens
- Mus musculus
- Caenorhabditis elegans
- Pyrrhula pyrrhula
organisms_ner:
- Caenorhabditis elegans
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC6218675
filename: fphys-09-01533-g0002.jpg
figlink: /pmc/articles/PMC6218675/figure/F2/
number: F2
caption: Summary of the potential treatments tested so far in EDMD. Schematic drawing
  representing several treatment strategies that have been developed for EDMD. The
  portrayed treatments target diverse mechanisms occurring either in the cytoplasm,
  e.g., autophagy in the lysosomes, or in the nucleus, including exon-skipping or
  trans-splicing strategies. The treatment strategies addressed to EDMD have generally
  been developed to target MAPK signaling pathway or to induce autophagy and these
  include different inhibitors of components of these pathways such as selumetinib
  or temsirolimus. To target apoptosis, the utilization of shRNA specific to Fox O1
  and 3 has been developed. Others treatments and strategies such as the use of paclitaxel
  to stabilize microtubules or gene therapy to convert the mutant transcript into
  a normal transcript or remove an in-frame exon containing a mutation have been studied.
  AKT, protein kinase B; ASK1, apoptosis signal-regulating kinase 1; ASO, antisense
  oligonucleotide; ERK, extracellular signal-regulated kinase; FoxO, forkhead box
  O; MEK1/2, MAPK/ERK kinase 1/2; MEKK1/4, mitogen-activated protein kinase kinase
  kinase 1/4; MKK3/6, mitogen-activated protein kinase kinase 3/6; MLK3, mitogen-activated
  protein kinase kinase kinase 11; mTORC1, mammalian target of rapamycin complex 1;
  PI3K, Phosphoinositide 3-kinase; Raf, proto-oncogen serine/threonine-protein kinase;
  TAK1, mitogen-activated protein kinase kinase kinase 7.
papertitle: The Pathogenesis and Therapies of Striated Muscle Laminopathies.
reftext: Astrid Brull, et al. Front Physiol. 2018;9:1533.
year: '2018'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9030644
figid_alias: PMC6218675__F2
figtype: Figure
redirect_from: /figures/PMC6218675__F2
ndex: c3c6435e-df11-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6218675__fphys-09-01533-g0002.html
  '@type': Dataset
  description: Summary of the potential treatments tested so far in EDMD. Schematic
    drawing representing several treatment strategies that have been developed for
    EDMD. The portrayed treatments target diverse mechanisms occurring either in the
    cytoplasm, e.g., autophagy in the lysosomes, or in the nucleus, including exon-skipping
    or trans-splicing strategies. The treatment strategies addressed to EDMD have
    generally been developed to target MAPK signaling pathway or to induce autophagy
    and these include different inhibitors of components of these pathways such as
    selumetinib or temsirolimus. To target apoptosis, the utilization of shRNA specific
    to Fox O1 and 3 has been developed. Others treatments and strategies such as the
    use of paclitaxel to stabilize microtubules or gene therapy to convert the mutant
    transcript into a normal transcript or remove an in-frame exon containing a mutation
    have been studied. AKT, protein kinase B; ASK1, apoptosis signal-regulating kinase
    1; ASO, antisense oligonucleotide; ERK, extracellular signal-regulated kinase;
    FoxO, forkhead box O; MEK1/2, MAPK/ERK kinase 1/2; MEKK1/4, mitogen-activated
    protein kinase kinase kinase 1/4; MKK3/6, mitogen-activated protein kinase kinase
    3/6; MLK3, mitogen-activated protein kinase kinase kinase 11; mTORC1, mammalian
    target of rapamycin complex 1; PI3K, Phosphoinositide 3-kinase; Raf, proto-oncogen
    serine/threonine-protein kinase; TAK1, mitogen-activated protein kinase kinase
    kinase 7.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - mek-1
  - mek-2
  - jnk-1
  - ras
  - Hras
  - Kras
  - Rem1
  - Nr2c2
  - Map3k7
  - Map3k5
  - Kcnk7
  - Map3k11
  - Pik3r1
  - Zhx2
  - Map2k1
  - Map2k2
  - Akt1
  - Hgf
  - Klrb1c
  - Tac1
  - Mapk3
  - Mapk1
  - Crk
  - Grap2
  - Syp
  - Mapk14
  - Ahsa1
  - Nprl3
  - Mpg
  - Krt32
  - Map2k6
  - Mapk8
  - Mapk10
  - Mapk9
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - KRAS
  - HRAS
  - NRAS
  - MAP3K7
  - NR2C2
  - MAP3K5
  - MAP3K11
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K1
  - MAP2K2
  - AKT1
  - AKT2
  - AKT3
  - CD160
  - B3GAT1
  - MTOR
  - RPTOR
  - CRK
  - AIMP2
  - GRAP2
  - AHSA1
  - POLDIP2
  - FOXO1
  - FOXO3
  - FOXO4
  - FOXO6
  - MPG
  - MAP2K6
  - MKP-4
  - p38b
  - rl
  - Ras64B
  - Ras85D
  - Tak1
  - Ask1
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Raf
  - Dsor1
  - Akt
  - slou
  - Crtc
  - lic
  - Nurf-38
  - Ebp
  - p38a
  - Hrb87F
  - p38c
  - foxo
  - del
  - tx
  - mirr
  - fs(1)de1
  - tRNA:Lys-CTT-1-7
  - tRNA:Lys-CTT-1-12
  - tRNA:Lys-CTT-1-5
  - tRNA:Lys-CTT-1-13
  - tRNA:Lys-CTT-1-8
  - tRNA:Lys-CTT-1-11
  - tRNA:Lys-CTT-1-2
  - tRNA:Lys-CTT-1-1
  - tRNA:Lys-CTT-1-10
  - tRNA:Lys-CTT-1-9
  - tRNA:Lys-CTT-1-6
  - tRNA:Lys-CTT-1-4
  - tRNA:Lys-CTT-1-3
  - PDS8059
  - Selumetinib
  - ARRY-371797
  - Temsirolimus
  - AAG
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
